Reynders McVeigh Capital Management LLC Lowers Position in Johnson & Johnson $JNJ

Reynders McVeigh Capital Management LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 76,826 shares of the company’s stock after selling 4,589 shares during the period. Reynders McVeigh Capital Management LLC’s holdings in Johnson & Johnson were worth $11,735,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the period. United Bank increased its stake in shares of Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after purchasing an additional 4,876 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in shares of Johnson & Johnson by 9.4% during the first quarter. Steward Partners Investment Advisory LLC now owns 361,775 shares of the company’s stock valued at $59,997,000 after purchasing an additional 31,232 shares during the last quarter. LeConte Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $467,000. Finally, Ethos Financial Group LLC grew its stake in shares of Johnson & Johnson by 213.4% in the 1st quarter. Ethos Financial Group LLC now owns 17,984 shares of the company’s stock worth $2,743,000 after buying an additional 12,245 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent research reports. Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Loop Capital set a $190.00 price target on Johnson & Johnson in a report on Wednesday, October 22nd. BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday. Bank of America increased their price objective on shares of Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research report on Wednesday, October 15th. Finally, HSBC reaffirmed a “buy” rating and issued a $240.00 target price on shares of Johnson & Johnson in a report on Wednesday. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $207.55.

Johnson & Johnson Trading Up 0.8%

Shares of JNJ stock opened at $211.65 on Monday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $212.27. The stock has a market capitalization of $509.93 billion, a P/E ratio of 20.43, a P/E/G ratio of 2.36 and a beta of 0.36. The firm’s 50 day moving average is $196.09 and its 200 day moving average is $177.42.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.